Shots:
- The companies collaborated to research, develop & commercialize small molecules directed against the GPR75 target with the potential to treat obesity and related co-morbidities
- The collaboration builds on the findings from the Regeneron Genetics Center of rare genetic mutations in the GPR75 gene associated with protection against obesity and on early joint research initiated soon after the discovery of the target
- The companies will evenly split R&D costs and will equally share profits in future
Click here to read full press release/ article | Ref: PRNewswire | Image: Regeneron
The post AstraZeneca and Regeneron Collaborate to Research, Develop and Commercialize Therapies for Obesity first appeared on PharmaShots.
